Skip to main content
Premium Trial:

Request an Annual Quote

Expedeon, Protein Discovery to Merge

NEW YORK (GenomeWeb News) – Expedeon and Protein Discovery today announced that they have signed a merger agreement.

Under the terms of the deal, the new company will keep the Expedeon name and remain headquartered in Cambridge, UK. Heikki Lanckriet, founder and CEO of Expedeon, will be the CEO of the new firm. Chuck Witkowski, founder and CEO of Protein Discovery, will join Expedeon's board of directors, the firms said.

Financial terms of the deal were not disclosed.

In addition to its Cambridge location, Expedeon has offices in San Diego. Its products include RunBlue electrophoresis precast gels, InstantBlue protein stain, and Nvoy protein stabilization products.

Protein Discovery, headquartered in Knoxville, Tenn., develops products for protein analysis. Its flagship product is the GelFree 8100 Fractionation System for partitioning complex protein mixtures into user-selectable, liquid-phase molecular weight fractions. It also provides consumables for the enhancement of data.

"By combining our businesses, we have an opportunity to create substantial value for our customers, shareholders, and other key stakeholders as we extend our innovative solutions to customers around the world," Witkowski said in a statement.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.